Automated differential cell counter downclassification to Class II sought by Abbott.
This article was originally published in The Gray Sheet
Executive Summary
AUTOMATED DIFFERENTIAL CELL COUNTER DOWNCLASSIFICATION TO CLASS II is justified by technological advances that have minimized the risks of user infection and improper diagnosis, Abbott Diagnostics argues in a Sept. 21 reclassification petition. Abbott asks FDA to downclassify from Class III to Class II automated differential cell counters (ADCCs) "that use flow-cytometric technology to enumerate abnormal cells of the blood."
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.